Singapore, July 16: AbbVie employees in Asia participated in the tenth Week of Possibilities (WOP), the AbbVie Foundation ...

A federal court in Missouri has dismissed a legal challenge by drugmaker AbbVie to the state’s new 340B contract pharmacy law, which aims to regulate how pharmaceutical companies interact with ...

This was the stock's third consecutive day of losses.

AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, through an exclusive licensing agreement that ...

AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the stock jumped 3.4% on the ...

AbbVie’s ABBV stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since early July. The 50-day ...

Under [the plaintiffs'] reading, virtually all pharmaceutical product-support services would qualify as a kickback,” U.S.

AbbVie has updated its 2025 earnings guidance after taking an $823 million acquired in-process R&D (IPR&D) expense in Q2.

The U.S. District Court for the Eastern District of Missouri July 11 granted a motion by the state to dismiss claims by ...

According to the update, the $823 million expense is related to acquired IPR&D, typically incurred through collaborations, ...

There’s really no such thing as a “no brainer” stock pick. I’d say that some opportunities are more compelling than others.

Abbott Laboratories is a dividend growth machine that's known for consistency. AbbVie's dividend has more than quadrupled ...